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Abstract
At present, we are facing coronavirus disease (COVID)-19 pandemic caused by the severe acute respiratory 
syndrome coronavirus-2 with several treatment choices and reports of different treatment outcomes. Chloroquine 
and hydroxychloroquine use for the management of severely ill patients started as a quite enthusiastic treatment 
option, following several small clinical trials, case series reports, public authorities, and media affirmation. However, 
the evidence we have so far is conflicting and some national societies and professional institutions implicate that we 
should wait for definite treatment recommendations until there are solid data for or against the use of these drugs. 
Until we have more powerful evidence in our hands, we should be aware of safety issues of the old drugs for the 
new application in the emergency state we are facing today with the COVID-19 pandemic. We performed a concise 
review of strengths, limitations, and awareness for chloroquine and hydroxychloroquine use for COVID-19 infection 
treatment based on the evidence the science has today.
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Introduction
Chloroquine and its analog hydroxychloroquine, 
drugs that had been used to treat malaria and systemic 
lupus erythematosus, rheumatoid arthritis, are recently 
promoted as a potential treatment for the coronavirus 
disease (COVID)-19. Initial results on the efficacy of 
chloroquine in severe acute respiratory syndrome 
caused by coronavirus-2 (SARS-CoV-2)  are derived 
from in vitro studies [1]. The first results from patients 
with SARS-CoV-2-related pneumonia and chloroquine 
efficacy come form China [2].
Hydroxychloroquine as an analog of chloroquine 
with less gastric intolerance and less concerns for drug 
interactions was found in vitro to be more potent than 
chloroquine in inhibiting SARS-CoV-2 [3].
Food and drug administration (FDA) allowed 
the use of these drugs since April 2020 to certain 
hospitalized patients where health-care providers and 
patients are provided with information about the risks 
of these drugs [4]. However, after first enthusiasm, 
FDA has expressed caution against the use of these 
drugs for COVID-19 outside of the hospital settings or 
a clinical trial due to the risk of heart rhythm problems 
and close supervision was strongly recommended. 
Clinical trials are planned and some have been 
underway to determine efficacy and safety of these 
drugs in the treatment of COVID-19 infection. At the 
beginning of April 2020, World Health Organization 
has started a multi-arm, multi-country clinical trial for 
potential coronavirus therapies based on evidence 
from laboratory, animal, and clinical studies, among 
which chloroquine and hydroxychloroquine treatment is 
included in the study.
Rational to use chloroquine analog lays in 
the fact that this drug is found to be effective against 
a variety of viral infections by inhibiting acidification 
of endosomes during the replication of the virus and 
infection and by their immunomodulatory effects [5]. 
Therapeutic agents such as chloroquine analogs, acting 
with the prevention of activation of macrophages, and 
inhibition of the secretion of tumor necrosis factor α and 
interleukin 6 from various cells would express benefits 
in the treatment of viral infections [6], [7].
Materials and Methods
A literature review was performed using PubMed 
to identify relevant articles published through April 15, 
2020. Used search terms were coronavirus, COVID-19, 
SARS-CoV-2, and chloroquine, hydroxychloroquine. 
This search resulted in 59 total articles. Additional 
T1 - Thematic Issue “Coronavirus Disease (COVID-19)” Narrative Review Article
204 https://www.id-press.eu/mjms/index
relevant articles were identified from the review of 
citations referenced. Case reports were also included.
The search terms COVID-19 or coronavirus or 
SARS-COV-2 and chloroquine or hydroxychloroquine 
on clinicaltrials.gov resulted in 14 active trials as of 
April 15, 2020. Ten of the trials are already recruiting 
patients, four still not recruiting patients. Seven of them 
are testing chloroquine or hydroxychloroquine alone, 
or controlled with placebo, three are testing low versus 
high dose hydroxychloroquine, and four are testing 
hydroxychloroquine versus hydroxychloroquine and 
azithromycin.
Discussion
Chloroquine, as an antimalarial drug, present 
at the pharmaceutical market more than 70 years has 
been tested regarding its safety profile multiple times. 
For many decades, people visiting malaria-endemic 
geographic areas received chloroquine prophylaxis and 
continued it for months after return in their homelands. 
In addition, some local residents in African countries 
took chloroquine continuously without any remarkable 
side effects. Hydroxychloroquine, on the other hand, 
has been used for a long time at much higher doses (up 
to 600 mg/day) for the treatment of certain autoimmune 
diseases. Regarding the longevity of clinical use and 
number of treated patients, nowadays, we can easily 
talk about good established safety profile of these drugs.
However, in the circumstances of acute viral 
infection with sometimes severe clinical presentation, 
attacking multiple systems, producing electrolyte, 
and metabolic changes, treatment with chloroquine/
hydroxychloroquine may lead to dangerous adverse 
effects.
Results from clinical studies
After the initial modest positive results, the 
problem had appeared when many hospitals have simply 
been giving these drugs to all infected patients, without 
proven efficacy, concerning that treatment is relatively 
safe. The reports in literature from France, Brazil, China, 
US are conflicting; some do not include control groups, 
many have a small number of participants and have 
no power to draw conclusions, and conclusions are 
conflicting.
Published studies are summarized in Table 1.
The earliest published studies from China 
and France have been widely criticized because 
there was no control group to compare treated versus 
untreated patients. Some researchers even called this 
report anecdotal. In the open-label, non-randomized 
study, Gautret et al. reported 100% viral clearance in 
nasopharyngeal swabs in six patients after 5–6 days of 
treatment with hydroxychloroquine and azithromycin [8]. 
Such a rapid and full viral clearance was quite unexpected 
to other authors. A study from China in patients with 
COVID-19 infection did not found any difference in 
virologic clearance with, or without treatment with 
hydroxychloroquine, and even more no difference in the 
clinical course of the disease [9].
A small double-blind, randomized study in Brazil 
(81 patients) was discontinued early for safety reasons 
after patients on a higher dose of chloroquine showed 
increased mortality due to QTc interval prolongation 
on recorded standard 12 lead electrocardiogram and 
associated proarrhythmias [10].
Despite the again small size of the previous 
study, infectologists and drug safety experts express 
their opinion that the study provided further evidence 
that chloroquine and hydroxychloroquine can pose 
significant harm to some patients, specifically the risk of 
a fatal arrhythmia. Patients in Brazilian study were also 
given azithromycin, which also prolongs QTc interval. It 
seems that we need more data at every level.
Barbosa et al. decided to publish preliminary 
results, although their dataset is growly rapidly 
because of concerning safety signals [11]. They 
showed that hydroxychloroquine did not appear to 
have a beneficial effect on meaningful clinical outcome 
measures of mortality, lymphopenia reconstitution, 
Table 1: Published studies about treatment with chloroquine or hydroxychloroquine for COVID-19 disease
Title Drug Type Number of participants Results
Hydroxychloroquine and azithromycin as a 
treatment of COVID-19: results of an open-label 
non-randomized clinical trial [8]
Hydroxychloroquine 200 mg × 3 and 
azithromycin, versus placebo
Open-label 
non-randomized
36 Improved virologic clearance in treatment 
arm addition of azithromycin resulted in 
superior viral clearance
A pilot study of hydroxychloroquine in treatment 
of patients with common COVID-19 [9]
Hydroxychloroquine, 400 mg, daily for 5 
days plus standard of care or standard care 
alone in a 1:1 fashion; 
Open-label 30 No
difference in virologic outcomes
Chloroquine diphosphate for the treatment of 
severe acute respiratory syndrome secondary to 
SARS-CoV2 (CloroCOVID19) NCT04323527 [10]
Low dose chloroquine diphosphate (450 
mg), 5 days versus high dose (600 mg) 10 
days
Double-blind, 
randomized 
adaptive clinical trial
440 ongoing data 
published for 81 pts.
Higher dose of chloroquine for 10 days was 
associated with more toxic effect and lethality, 
particularly affecting QTc prolongation
Clinical outcomes of hydroxychloroquine in 
hospitalized patients with COVID-19: A quasi-
Randomized comparative study [11]
Hydroxychloroquine and supportive care 
versus supportive care alone initial loading 
dose of 400 mg b.i.d 1–2 days and 3–4 
subsequent days 200 mg −400 mg o.d.
Quasi-randomized 63 Hydroxychloroquine was associated 
with an increased need for escalation 
of respiratory support. No benefits 
of hydroxychloroquine on mortality, 
lymphopenia, or neutrophil-to-lymphocyte 
ratio improvement
Efficacy of hydroxychloroquine in patients with 
COVID-19: results of a randomized clinical trial
ChiCTR2000029559 [12]
Hydroxychloroquine 400 mg/d (200 mg/
bid) between days 1 and 5 versus standard 
treatment only.
Randomized 
parallel-group trial
62 Hydroxychloroquine use shortened time to 
clinical recovery
COVID-19: Coronavirus disease-19.
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neutrophil-to-lymphocyte ratio, or risk for intubation. 
Patients in hydroxychloroquine arm appeared to have 
a worse clinical outcome in terms of need of respiratory 
support [11]. These results were in contrast to previously 
published results from Chen et al., showing shortened 
time to clinical recovery in hydroxychloroquine group in 
comparison with the control group (body temperature 
recovery time and cough remission time) [12].
The true answer to whether chloroquine 
or hydroxychloroquine has a beneficial effect for 
COVID-19 patients can only be obtained with a 
prospective randomized clinical study (Table 1).
Recommendations
According to the tendency of doctors and 
hospitals to give chloroquine or hydroxychloroquine, 
especially to severe ill patients, some associations, 
expert groups have published recommendations, and 
some refrain from making recommendations until the 
results of relevant clinical studies come out (Table 2).
Table 2: Available guidance about the treatment with 
chloroquine/hydroxychloroquine up to April 2020
Multicenter collaboration group of 
Department of Science and Technology 
of Guangdong Province and Health 
Commission of Guangdong Province 
for chloroquine in the treatment of 
novel coronavirus pneumonia. Expert 
consensus on chloroquine phosphate 
for the treatment of novel coronavirus 
pneumonia.
Zhonghua Jie He He Hu Xi Za Zhi. 20 
February 2020; 43 (0): E019.
The Panel recommends the use of the 
chloroquine at a dose of 500 mg BID for 10 
days.
Alternatively, you can use if it were not 
available chloroquine, hydroxychloroquine 
200 mg BID.
Diagnosis and treatment protocol for 
novel coronavirus pneumonia (Trial 
Version 7)
(Released by National Health Commission 
and State Administration of Traditional 
Chinese Medicine on March 3, 2020)
Chloroquine phosphate (500 mg bid for 7 
days for adults aged 18–65 with body weight 
over 50 kg; 500 mg bid for Days 1 and 2 and 
500 mg qd for Days 3–7 for adults with body 
weight <50 kg)
Handbook for the care of people with 
disease-COVI 19
Edition 2.0, March 13, 2020
SIMIT
Italian Society of Infectious and Tropical 
Diseases SECTION Regione Lombardia
Chloroquine/hydroxychloroquine 
in prophylaxis for COVID-19 is not 
recommended. At present, there is no 
evidence of efficacy of this drug in the 
prevention of disease COVID-19.
Chloroquine 500 mg twice daily for 20 days 
OR hydroxychloroquine 200 mg BID in 
patients with COVID-19 irrespective of the 
severity of symptoms
ESC guidance for the diagnosis and 
management of CV disease during the 
COVID-19 pandemic
escardio.org/Education/
COVID-19-and-Cardiology/
ESC-COVID-19-Guidance
Results of ongoing clinical trials of 
chloroquine/hydroxychloroquine efficacy 
in the treatment of SARS-CoV2 should be 
awaited before definite recommendations are 
provided for or against the use of these drugs
Clinical management of severe acute 
respiratory infection when COVID-19 is 
suspected
Interim guidance
March 13, 2020, |
World Health Organization
No recommendation
COVID-19
Interim Clinical Guidance for Management 
of Patients with confirmed COVID-19
CDC Center for Disease Control and 
Prevention
No recommendation
COVID-19: Coronavirus disease 2019.
Dose recommendations for chloroquine or 
hydroxychloroquine
After conducted clinical trials by Chinese teams, 
recommend a dose of chloroquine phosphate was 
500 mg of twice a day in patients with mild, moderate, 
and severe forms of COVID-19 pneumonia [2].
With huge experience over the past 5 years in 
patients with long-term treatment (>1 year), for different 
indications, Lagier et al. recommended dosage for 
hydroxychloroquine of 600 mg/day with which concentration 
of 1 μg/mL is reached [13]. They also suggest administration 
of loading dose, followed by a maintenance dose and 
express their opinion that activity of hydroxychloroquine on 
viruses is probably the same as that of chloroquine, giving 
preference to hydroxychloroquine [13].
As a specific treatment for COVID-19 disease, 
Yao et al. recommended that the optimal dosing regimen 
for hydroxychloroquine should be a loading dose of 
400 mg twice daily for 1 day followed by 200 mg twice 
daily [3]. However, similarly, as for Whipple disease, 
some authors make alternative recommendations of 
600 mg total daily dose [14].
Effects on QT interval and 
recommendations
Chloroquine and hydroxychloroquine are listed 
as drugs that have known risk of polymorphic ventricular 
arrhythmia “Torsades de Pointes” (TdP), due to QT 
interval prolongation at crediblemeds.org. They have 
proarrhythmogenic effect through blocking IKr (rapid 
delayed rectifier potassium current) channels, causing 
a significant reduction in the amplitude of potassium tail 
currents [15] (Figure 1).
Figure 1: Hydroxychloroquine effect on electrocardiogram
The preliminary findings from the CloroCovid-19 
trial suggest that a higher dosage of chloroquine should 
not be recommended for the treatment of severe COVID-
19, especially in combination with azithromycin and/or 
oseltamivir, because of safety concerns [10]. Increased 
mortality was observed due to QTc interval prolongation 
and associated proarrhythmias [10] (Figure 1).
The most used formula for QTc interval 
calculation is the Bazett formula: 
2QTc=QT/ RR
European Society of Cardiology has recently 
released “Guidance for the Diagnosis and Management 
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of CV disease during the COVID-19 pandemic” last 
updated on April 21, 2020 [16]. Before administration 
of chloroquine or hydroxychloroquine therapy, there are 
some suggestions:
•	 Drug-drug interactions including antiviral, 
antiarrhythmic, and anticoagulation drugs 
should be considered;
•	 In hemodynamically stable patients with 
atrial fibrillation or flutter, discontinuation 
of antiarrhythmic drugs and initiation of 
rate control therapy to allow safe use of 
hydroxychloroquine as antiviral medication is 
a reasonable therapeutic option.
When chloroquine or hydroxychloroquine 
therapy is started, the following interventions should 
be considered in order to reduce the risk of malignant 
arrhythmia and death [16], [17]:
•	 Withholding the drugs in patients with baseline 
QT prolongation (especially QTc ≥500 ms) or 
with known congenital long QT syndrome.
•	 On-treatment ECGs are recommended 
to monitor cardiac rhythm and rule out a 
significant prolongation of QTc (>500 ms, or by 
>60 ms vs. baseline)
•	 It is worth exploring alternative ECG monitoring 
methods (e.g., monitoring leads, smartphone-
enabled mobile ECG, and handheld devices);
•	 Correction of hypokalemia to levels of >4 mEq/L 
targeting >4.5 mEq/L and hypomagnesemia to 
levels of >2 mg/dL.
The safety of QT-prolonging medications may 
be maximized by close monitoring and optimization of 
these factors. A risk score has been derived and validated 
by Tisdale et al., for the prediction of drug-associated 
QT prolongation among cardiac-care-unit-hospitalized 
patients [18]. Factors incorporated in this score are: 
Female gender, age ≥68 years, concomitant use of loop 
diuretics, antiarrhythmic drugs, and comorbidities such 
as acute myocardial infarction, heart failure, sepsis, 
hypokalemia, and admission QTc ≥450 ms. According 
to present additional factors, Tisdale score predicts low, 
medium, or high risk of drug-associated QT prolongation. 
The goal of QTc screening in this setting is not to identify 
patients whom are not candidates for therapy but 
to identify those who are at increased risk for TdP so 
aggressive countermeasures may be implemented [19].
Conclusion
There is a lack of evidence regarding the 
efficacy and risk of different treatment strategies in 
patients with COVID-19 disease. In this circumstance, 
facing deadly disease, many hospitals have simply 
been giving hydroxychloroquine to patients, reasoning 
that it might help and probably will not hurt because it 
is relatively safe.
To stay on a safe side, before we get relevant 
results from ongoing clinical studies in all patients 
undergoing antiviral treatment, including chloroquine 
or hydroxychloroquine, it is necessary to correct 
modifiable predisposing factors to QTc prolongation: 
Electrolyte imbalances, concomitant unnecessary 
drugs, and bradycardia.
Not to forget, while the patient is on chloroquine 
or hydroxychloroquine treatment ECG should be 
monitored also for conduction disturbances, despite 
these are rare and referred only during long-term 
treatment.
Definite recommendations will emerge once 
the results of ongoing clinical trials of chloroquine/
hydroxychloroquine efficacy in the treatment of 
SARS-CoV2 will be published.
Until than cautiously use is wise, with an 
awareness of side effects.
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